BAXTER INTERNATIONAL INC (BAX) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BAX - US0718131099 - Common Stock
BAX Key Statistics, Chart & Performance
The current stock price of BAX is 20.41 USD. In the past month the price increased by 10.84%. In the past year, price decreased by -30.15%.
BAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.46 | 220.89B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.76 | 209.86B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.42 | 146.15B | ||
| SYK | STRYKER CORP | 27.87 | 140.38B | ||
| BDX | BECTON DICKINSON AND CO | 14.05 | 57.81B | ||
| IDXX | IDEXX LABORATORIES INC | 56.34 | 56.73B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.9 | 49.06B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.64 | 38.98B | ||
| RMD | RESMED INC | 25.07 | 36.23B | ||
| DXCM | DEXCOM INC | 37.73 | 27.37B | ||
| PODD | INSULET CORP | 65.24 | 20.97B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.41B |
Related stock screener links
About BAX
Company Profile
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Company Info
BAXTER INTERNATIONAL INC
One Baxter Parkway
Deerfield ILLINOIS 60015 US
CEO: Jose E. Almeida
Employees: 38000
Phone: 12249482000
BAXTER INTERNATIONAL INC / BAX FAQ
What does BAX do?
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Can you provide the latest stock price for BAXTER INTERNATIONAL INC?
The current stock price of BAX is 20.41 USD. The price decreased by -0.68% in the last trading session.
Does BAX stock pay dividends?
BAXTER INTERNATIONAL INC (BAX) has a dividend yield of 0.21%. The yearly dividend amount is currently 1.16.
What is the ChartMill technical and fundamental rating of BAX stock?
BAX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy BAX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BAX.
What is the market capitalization of BAX stock?
BAXTER INTERNATIONAL INC (BAX) has a market capitalization of 10.49B USD. This makes BAX a Large Cap stock.
What is the Short Interest ratio of BAXTER INTERNATIONAL INC (BAX) stock?
The outstanding short interest for BAXTER INTERNATIONAL INC (BAX) is 6.55% of its float.
BAX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BAX. When comparing the yearly performance of all stocks, BAX is a bad performer in the overall market: 84.88% of all stocks are doing better.
BAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BAX. While BAX is still in line with the averages on profitability rating, there are concerns on its financial health.
BAX Financial Highlights
Over the last trailing twelve months BAX reported a non-GAAP Earnings per Share(EPS) of 2.41. The EPS decreased by -19.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.62% | ||
| ROE | -4.71% | ||
| Debt/Equity | 1.21 |
BAX Forecast & Estimates
25 analysts have analysed BAX and the average price target is 24.55 USD. This implies a price increase of 20.28% is expected in the next year compared to the current price of 20.41.
For the next year, analysts expect an EPS growth of -11.91% and a revenue growth 4.93% for BAX